A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

BACKGROUND: This study evaluated whether an addition of bevacizumab to erlotinib improves clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer (NSCLC). METHODS: This is an open‐label, multicenter, randomized Phase 2 study in South Korea. Chemonaïve patients with Stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Youngjoo, Kim, Hye Ryun, Hong, Min Hee, Lee, Ki Hyeong, Park, Keon Uk, Lee, Geon Kook, Kim, Hyae Young, Lee, Soo‐Hyun, Lim, Kun Young, Yoon, Sung Jin, Cho, Byoung Chul, Han, Ji‐Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100207/
https://www.ncbi.nlm.nih.gov/pubmed/36451343
http://dx.doi.org/10.1002/cncr.34553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100207/
https://www.ncbi.nlm.nih.gov/pubmed/36451343
http://dx.doi.org/10.1002/cncr.34553

Ejemplares similares